NL-OMON51829招募中不适用
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments - CPDR001X2X01B
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- ovartis
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Signed informed consent must be obtained prior to participation in the study.
- •2. Subject is currently enrolled in a pre-defined Novartis-sponsored study and
- •is receiving
- •spartalizumab as single agent or in combination with other study treatment.
- •3. Subject is currently deriving clinical benefit from the study treatment, as
- •determined by the
- •investigator.
- •4. Subject has demonstrated compliance, as assessed by the investigator, with
- •protocol requirements.
- •5. Subject is willing and able to comply with the scheduled visits and
- •treatment plans.
排除标准
- •Subject has been permanently discontinued from spartalizumab in the parent
- •protocol for any reason other than enrollment in the CPDR001X2X01B study.
- •Subject does not meet the criteria specified in the parent protocol criteria
- •for continued study treatment.
- •Subject not willing to comply with the contraception requirements outlined in
- •the exclusion criteria of the parent protocol.
研究者
相似试验
进行中（未招募）
1 期
A rollover study for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib alone or in combination with other agentsEUCTR2016-000293-37-FRovartis Pharma Services AG40
进行中（未招募）
1 期
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatmentsDifferent types of advanced cancerMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10028997Term: Neoplasm malignant Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-508841-42-00ovartis Pharma AG119
招募中
2 期
An open-label, multi-center rollover protocol for patients
who have participated in a Novartis-sponsored ribociclib
(LEE011) study and are continuing to benefit from
ribociclib as single agent or in combination with other
investigational treatments2024-511125-61-00Novartis Pharma AG1
招募中
1 期
An open-label, multi-center rollover protocol for patientswho have participated in a Novartis-sponsored ribociclib(LEE011) study and are continuing to benefit fromribociclib as single agent or in combination with otherinvestigational treatmentsCTIS2024-511125-61-00ovartis Pharma AG4
进行中（未招募）
1 期
A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.Biliary atresiaMedDRA version: 20.0Level: LLTClassification code 10004653Term: Biliary atresiaSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10004654Term: Biliary atresia, congenitalSystem Organ Class: 100000004850EUCTR2014-004693-42-FIIntercept Pharmaceuticals, Inc.72